Press Releases

Tuebingen, Germany, June 10, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver disease, today announced that the first patient has been dosed in their Phase Ib clinical trial of its lead candidate HRX-215. The trial is evaluating the safety and efficacy of HRX-215, an orally availableContinue reading "HepaRegeniX Doses First Patient in Phase Ib Trial with Small Molecule Inhibitor HRX-215 to Promote Liver Regeneration"

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results  Tuebingen, Germany, May 8, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, announced that the company’sContinue reading "HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025"

Tuebingen, Germany, April 15, 2025 – HepaRegeniX GmbH (“HepaRegeniX”), a clinical-stage company advancing novel therapies to treat acute and chronic liver diseases, today announced the second closing and completion of a €21.5 million financing round with the addition of Wellington Partners to its investor syndicate. HepaRegeniX plans to use the proceeds to complete its ongoingContinue reading "HepaRegeniX completes €21.5 million financing to support clinical advancement of HRX-215 for liver regeneration"

Elias Papatheodorou moves from Chair of Board to CEO and Managing Director of HepaRegeniX Preparations for upcoming clinical trials in the USA are ongoing Tuebingen (Germany), October 22, 2024 – HepaRegeniX GmbH, a clinical stage company developing a novel regenerative therapy for the treatment of acute and chronic liver diseases, today announced the appointment of Dr.Continue reading "HepaRegeniX appoints Dr. Martin Bonde as new Chair of the Board"

Funds to support Phase Ib clinical trial of HRX-215 in the US and an international multicenter Phase IIa clinical trial in liver regeneration Elias Papatheodorou moves from Chair of the Board to CEO of HepaRegeniX Dr. Linda Greenbaum joins HepaRegeniX as CMO Tuebingen (Germany), July 10, 2024 – HepaRegeniX GmbH, a clinical stage company developing aContinue reading "HepaRegeniX raises €15 million Series C round to advance clinical development of HRX-215 for liver regeneration"

Clinical and pre-clinical data generated from collaborations between the Tuebingen University Hospital, researchers from the Mayo Clinic in Rochester (USA) and HepaRegeniX HRX-215 proved to be safe and well tolerated in healthy volunteers, pre-clinical data showed increased regeneration of liver cells HRX-215 to be further developed to usher in a new era in oncological liverContinue reading "HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell"

Tübingen (Germany), November 23, 2022 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Dr. Andreas Busch as Senior Advisor. Dr. Busch will help the Company to further advance the development of MKK4 inhibition, a first-in-class treatment paradigmContinue reading "HepaRegeniX appoints Dr. Andreas Busch as Senior Advisor"

HRX-0215 proved to be safe and well tolerated in healthy volunteers Tubingen (Germany), May 12, 2022 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the successful conclusion and top-line results of its Phase 1 clinical trial for its lead drug candidate HRX-0215.Continue reading "HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor"

Tubingen (Germany), March 30, 2022 – HepaRegeniX GmbH, a clinical stage company developing novel regenerative therapy approaches for the treatment of acute and chronic liver diseases, announced today the appointment of Elias Papatheodorou as chairman of the board of directors with executive functions. He foll0ws Dr. Graham Dixon who served as Chairman on the Board of HeparegeniXContinue reading "HepaRegeniX appoints Elias Papatheodorou as new Chairman of the Board of Directors"

New data supporting therapeutic potential of MKK4 inhibition in advanced liver diseases Tubingen (Germany), November 04, 2021 – HepaRegeniX GmbH, a clinical stage company developing novel therapies for the treatment of acute and chronic advanced liver diseases, announced today two presentations at renowned scientific conferences that will disclose new data on HepaRegenix’ first-in-class approach to liverContinue reading "HepaRegeniX to present key results on MKK4 inhibitors and their therapeutic efficacy at upcoming scientific conferences"

HRX-0233 is a new MKK4 inhibitor and the 2nd drug candidate from the company´s small molecule-based drug discovery platform HRX-0223 is being investigated for the treatment of tumors with mutated KRAS gene, a common oncogenic driver in combination with other treatments KRAS mutations are associated with poor prognosis Tubingen (Germany), October 20, 2021 – HepaRegeniX GmbH,Continue reading "HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination therapy"

HRX-0215 is the first compound from the company´s small molecule-based drug discovery platform ready for clinical testing Tubingen (Germany), August 10, 2021 – HepaRegeniX GmbH, a clinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today the first dosing of its lead drug candidate HRX-0215 in a Phase 1Continue reading "HepaRegeniX initiates first-in-man Phase 1 trial for its lead MKK4 inhibitor HRX‑0215"

Tubingen (Germany), December 3, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today that treatment with selective Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4) inhibitors over a three month period reduced hepatic steatosis and liver damage in a murine model of nonalcoholic steatohepatitisContinue reading "HepaRegeniX achieves further milestone related to proof of safety and efficacy for MKK4 inhibition in an advanced chronic liver disease model"

30 years of specialist knowledge in clinical operations to translate encouraging preclinical results into the clinic Tubingen (Germany), November 19, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today the appointment of Dr Markus Weissbach as Senior Clinical Advisor. Dr. Weissbach has overContinue reading "HepaRegeniX hires industry expert Dr. Markus Weissbach as Senior Clinical Advisor"

Tubingen (Germany), November 10, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today that an oral presentation highlighting preclinical data of the beneficial effects of MKK4 (Mitogen activated protein kinase kinase 4) inhibition on liver regeneration in non-rodent, large animal species models will be deliveredContinue reading "HepaRegeniX GmbH to deliver an oral presentation of preclinical results on MKK4 inhibition in liver regeneration at The Liver Meeting® 2020"

Tubingen (Germany), October 20, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today that Dr David Shapiro will join the company as Senior Medical Advisor. Dr. Shapiro has over 30 years of experience in the pharmaceutical and biotechnology industries. Formerly, Dr Shapiro wasContinue reading "HepaRegeniX GmbH hires industry veteran Dr David Shapiro as Senior Medical Advisor"

Preclinical data indicate unique liver disease treatment potential as demonstrated by strong liver regeneration and significant reduction in steatosis plus inhibition of apoptosis Tubingen (Germany), July 07, 2020 – HepaRegeniX GmbH, a preclinical stage company developing novel therapies for the treatment of acute and chronic liver diseases, announced today successful proof of efficacy for MKK4 inhibitorsContinue reading "HepaRegeniX GmbH achieves successful proof of efficacy in acute liver disease models for selected MKK4 inhibitors"

Tubingen (Germany), January 21, 2020 – HepaRegeniX GmbH, a preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases today announced the closing of its Series B financing round in excess of € 11 Mio. with contribution from all its existing investors namely Boehringer Ingelheim Venture Fund GmbH (BIVF), NovoContinue reading "HepaRegeniX GmbH secures Series B Financing in excess of € 11 Mio. to advance first drug candidate to the clinic"